ASCO 2014: Boehringer Ingelheim to present latest oncology research, including overall survival results for Giotrif® (afatinib) in advanced NSCLC
- Highly anticipated new overall survival data for Giotrif® (afatinib*) to be presented on June 2nd (3:00 - 6:00 PM, E Hall D2 [Abstract #8004 scheduled for 4:00 - 4:12 PM])
- 7 total abstracts accepted for Giotrif® (afatinib*), nintedanib** and BI 836845**: 1 for oral presentation and 6 posters
Corporate Chief
Medical Officer,
Boehringer
Ingelheim
Ingelheim, Germany, Friday, May 30 – Boehringer Ingelheim today announced that important new data will be presented from 7 abstracts for Giotrif® (afatinib*), nintedanib** and its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 30 May – 3 June 2014.
Data include results from global Phase III trials of afatinib in different patients with advanced non-small cell lung cancer (NSCLC):
- LUX-Lung 3 & LUX-Lung 6 overall survival analysis (abstract #8004, oral presentation): comparing first-line afatinib to chemotherapy in patients with advanced NSCLC with common epidermal growth factor receptor (EGFR) mutations
- LUX-Lung 5 (abstract #8019, poster session) evaluating continuation of afatinib with paclitaxel (a chemotherapy) versus investigator’s choice of chemotherapy alone in NSCLC patients whose disease had progressed on previous chemotherapy, erlotinib or gefitinib, and afatinib alone.
"We are excited to be presenting data from our oncology compounds in different groups of patients with cancer. Boehringer Ingelheim is dedicated to developing new treatment options that make a meaningful difference for patients with cancer. We are especially pleased to share with the oncology community the highly anticipated results of the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials," commented Professor Klaus Dugi, Corporate Chief Medical Officer, Boehringer Ingelheim.
Data of Boehringer Ingelheim (Investigational) Oncology Compounds at ASCO 2014
|
Title |
Authors |
Abstract Details |
|---|---|---|
|
Giotrif/Gilotrif (afatinib)* |
|
|
|
Overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) harboring common Epidermal Growth Factor Receptor mutations (EGFR M+): pooled analysis of two large phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) |
James Chih-Hsin Yang, Lecia V. Sequist, Martin Schuler, Tony Mok, Kenneth O’Byrne, Vera Hirsch, Sarayut L Geater, Caicun Zhou, Dan Massey, Victoria Zazulina, Yi Long Wu |
Monday, June 2 |
|
LUX-Lung 5: a randomized, open-label, phase III trial of afatinib (A) plus paclitaxel (P) versus investigator’s choice of chemotherapy (ICC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) who had progressed on erlotinib/gefitinib (E/G) and afatinib |
Martin Schuler, Chih-Hsin Yang, Keunchil Park, Jaafar Bennouna Yuh-Min Chen, Christos Chouaid, Filippo De Marinis, Jifeng Feng, Francesco Grossi, Dong-Wan Kim, Xiaoqing Liu, Shun Lu, Janos Strausz, Yuriy Vinnyk, Rainer Wiewrodt, Caicun Zhou, Vikram K. Chand, Bushi Wang, Joo-Hang Kim and David Planchard |
Tuesday, June 3 |
|
Nintedanib** |
|
|
|
Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D) |
Martin Reck, Anders Mellemgaard, Sergey V. Orlov, Maciej Jerzy Krzakowski, Joachim Von Pawel, Maya Gottfried, Igor Bondarenko, Mei-Lin Liao, Jose Barrueco, Julia Hocke, Rolf Kaiser, Silvia Novello, Jean-Yves Douillard, LUME-Lung 1 Study Group |
Saturday, May 31 |
|
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM)–an international, multicenter, randomized, doubleblind, placebo-controlled phase II study |
Giorgio V. Scagliotti, Natasha B. Leighl, Anna K. Nowak, Nick Pavlakis, Sanjay Popat, Jens Benn Sorensen, Jose Barrueco, Rolf Kaiser, Arsene-Bienvenu Loembe, Martha Mueller, Ute von Wangenheim, Martin Reck |
Saturday, May 31 |
|
Independent review of AGO-OVAR 12, a GCIG/ENGOT-intergroup phase III trial of nintedanib (N) in firstline therapy for ovarian cancer (OC) |
Gunnar Kristensen, Philipp Harter, Olivier Trédan, Martin Oliver Sailer, Aristotelis Bamias, Nicoletta |
Saturday, May 31 |
|
BI 836845 (IGF ligand antibody)** |
|
|
|
A Phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers |
Chia-Chi Lin, Kwang-Yu Chang, Dennis Chin-Lun Huang, Vicky Marriott, Ludy van Beijsterveldt, Li-Tzong Chen, Ann-Lii Cheng |
Sunday, June 1 |
|
Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumours |
Rihawi K, Ong M, Michalarea V, Bent L, Buschke S4, Bogenrieder T, Anthoney A, de Bono J, Twelves CJ |
Sunday, June 1 |
Notes to Editors
About Afatinib*: 
About Nintedanib**:
About Boehringer Ingelheim in Oncology:
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
Footnotes
*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the U.S. under the brand name GILOTRIF® for use in patients with distinct types of EGFR mutation-positive NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide.
**Nintedanib and BI 836845 are investigational compounds and are not yet approved. Their safety and efficacy have not yet been fully established.